Evidence map›Paper›PMID 33974712›Full record

ArticleCancer2021

Aspirin, ibuprofen, and reduced risk of advanced colorectal adenoma incidence and recurrence and colorectal cancer in the PLCO Cancer Screening Trial.

Kenechukwu Chudy-Onwugaje, Wen-Yi Huang, L Joseph Su, Mark P Purdue, Christine C Johnson, Lingxiao Wang, Hormuzd A Katki, Kathryn Hughes Barry, Sonja I Berndt

Open access · bronzeAbstract read
In one paragraph

Article in Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 29 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Kenechukwu Chudy-OnwugajeDivision of Gastroenterology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Wen-Yi HuangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-4440-3368
L Joseph SuFay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Mark P PurdueDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Christine C JohnsonDepartment of Public Health Sciences, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan.
Lingxiao WangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Hormuzd A KatkiDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Kathryn Hughes BarryDepartment of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland.
Sonja I BerndtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
National Institutes of Health · USHenry Ford Health System · USUniversity of Arkansas for Medical Sciences · USUniversity of Maryland, Baltimore · USUniversity of Pennsylvania · US

Funding

PLCO Trial Etiologic and Early Marker StudyZIACP010152 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MOORE, STEVEN · 2009 to 2025
$29.9M
Research Training in Gastroenterology and HepatologyT32DK067872 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI RAUFMAN, JEAN-PIERRE · 2005 to 2024
$7.2M
Epigenomic and transcriptomic markers of aggressive prostate cancer among African American menK07CA230182 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI BARRY, KATHRYN HUGHES · 2018 to 2023
$827k
NCI NIH HHS K07 CA230182NIDDK NIH HHS T32 DK067872
6 · The paper itself

Abstract

backgroundStudying the differential impact of aspirin and other nonsteroidal anti-inflammatory drugs across the stages of colorectal neoplasia from early adenoma to cancer is critical for understanding the benefits of these widely used drugs.

methodsWith 13 years of follow-up, the authors prospectively evaluated the association between aspirin and ibuprofen use and incident distal adenoma (1221 cases), recurrent adenoma (862 cases), and incident colorectal cancer (CRC; 2826 cases) among men and women in the population-based Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. With multivariable-adjusted models, odds ratio (ORs) and 95% confidence intervals (CIs) for adenoma incidence and recurrence and hazard ratios (HRs) and 95% CIs for incident CRC were determined.

resultsThe authors observed a significantly reduced risk of incident adenoma with ibuprofen use (≥30 vs <4 pills per month: OR, 0.76 [95% CI, 0.60-0.95]; P

conclusionsIn this large prospective study with long-term follow-up, a beneficial role for not only aspirin, but also ibuprofen, in preventing advanced adenoma and curbing progression to recurrence and cancer among older adults was observed.

Indexed as

AdenomaColorectal NeoplasmsAgedAspirinEarly Detection of CancerFemaleHumansIbuprofenIncidenceMaleProspective StudiesAspirinIbuprofenaspirincolorectal canceribuprofenincident adenomarecurrent adenoma

Identifiers

PMID33974712
PMCPMC8355096
OpenAlexW3162625093

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.